Pain in survivors of Ewing sarcoma: Prevalence, associated factors and prediction of recurrence.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
03 2021
Historique:
received: 05 06 2020
revised: 15 09 2020
accepted: 13 10 2020
pubmed: 13 11 2020
medline: 3 8 2021
entrez: 12 11 2020
Statut: ppublish

Résumé

While the prognosis of patients with Ewing sarcoma (EwS) is improving, little is known about the frequency of pain and its risk factors in survivors of EwS. This study aims to analyse the prevalence and risk factors of pain and its predictive value for recurrence. In patients with remission after treatment of EwS, frequency and characteristics of pain within the first 5 years of follow up were assessed retrospectively. Of 80 patients, 37 (46%) presented with at least one episode of pain. Chronic pain (>3 months) was observed in 10 patients (13%). Experience of at least one episode of pain was associated with prior combined local treatment (surgery and radiation compared to surgery alone; odds ratio [OR] 5.83, 95% confidence interval [CI] 1.43-34.9, P = .007). A total of 59 episodes of pain were observed, including 47 acute and 12 chronic episodes. Lower limb pain accounted for 46% (27/59) of all episodes of pain, and was associated with primary tumour of the pelvis or lower extremity (OR 4.29, 95% CI 1.18-18.21, P = .025), which represented 64% (51/80) of all EwS. The positive predictive value of pain for recurrence was only 12%. Pain is a common problem in survivors of EwS, which mostly affects the lower extremity, and should be regularly assessed. Interventions to reduce pain may be particularly important in patients with combined local treatment with surgery and radiation, who seem to be at considerably increased risk for pain. Patients presenting with pain should be examined for recurrence.

Sections du résumé

BACKGROUND
While the prognosis of patients with Ewing sarcoma (EwS) is improving, little is known about the frequency of pain and its risk factors in survivors of EwS. This study aims to analyse the prevalence and risk factors of pain and its predictive value for recurrence.
PATIENTS AND METHODS
In patients with remission after treatment of EwS, frequency and characteristics of pain within the first 5 years of follow up were assessed retrospectively.
RESULTS
Of 80 patients, 37 (46%) presented with at least one episode of pain. Chronic pain (>3 months) was observed in 10 patients (13%). Experience of at least one episode of pain was associated with prior combined local treatment (surgery and radiation compared to surgery alone; odds ratio [OR] 5.83, 95% confidence interval [CI] 1.43-34.9, P = .007). A total of 59 episodes of pain were observed, including 47 acute and 12 chronic episodes. Lower limb pain accounted for 46% (27/59) of all episodes of pain, and was associated with primary tumour of the pelvis or lower extremity (OR 4.29, 95% CI 1.18-18.21, P = .025), which represented 64% (51/80) of all EwS. The positive predictive value of pain for recurrence was only 12%.
CONCLUSION
Pain is a common problem in survivors of EwS, which mostly affects the lower extremity, and should be regularly assessed. Interventions to reduce pain may be particularly important in patients with combined local treatment with surgery and radiation, who seem to be at considerably increased risk for pain. Patients presenting with pain should be examined for recurrence.

Identifiants

pubmed: 33179838
doi: 10.1002/pbc.28801
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28801

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Grünewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewing sarcoma. Nat Rev Dis Primers. 2018;4:5.
Bölling T, Hardes J, Dirksen U. Management of bone tumours in paediatric oncology. Clin Oncol (R Coll Radiol). 2013;25:19-26.
Nazeer A, Kandil A, Zahra O, Soliman M. Clinicopathological features and treatment outcomes in Ewing's sarcoma patients: a 10-year experience of Alexandria Clinical Oncology Department. Indian J Med Paediatr Oncol. 2017;38:316-320.
Pappo AS, Dirksen U. Rhabdomyosarcoma, Ewing sarcoma, and other round cell sarcomas. J Clin Oncol. 2018;36:168-179.
Ranft A, Seidel C, Hoffmann C, et al. Quality of survivorship in a rare disease: clinicofunctional outcome and physical activity in an observational cohort study of 618 long-term survivors of Ewing sarcoma. J Clin Oncol. 2017;35:1704-1712.
Glare PA, Davies PS, Finlay E, et al. Pain in cancer survivors. J Clin Oncol. 2014;32:1739-1747.
Reinfjell T, Zeltzer L. A systematic review of self-reported pain in childhood cancer survivors. Acta Paediatr. 2020;109:56-70.
Lu Q, Krull KR, Leisenring W, et al. Pain in long-term adult survivors of childhood cancers and their siblings: a report from the Childhood Cancer Survivor Study. Pain. 2011;152:2616-2624.
Brown MR, Ramirez JD, Farquhar-Smith P. Pain in cancer survivors. Br J Pain. 2014;8:139-153.
Heinemann M, Ranft A, Langer T, et al. Recurrence of Ewing sarcoma: is detection by imaging follow-up protocol associated with survival advantage? Pediatr Blood Cancer. 2018;65:e27011.
Kuo PY, Yen JT, Parker GM, et al. The prevalence of pain in patients attending sarcoma outpatient clinics. Sarcoma. 2011;2011:813483.
Heinemann M, Ranft A, Jürgens H, et al. Ewing sarcoma during follow-up. Nuklearmedizin. 2017;56:233-238.
Stone AL, Karlson CW, Heathcote LC, Rosenberg AR, Palermo TM. Topical review: pain in survivors of pediatric cancer: applying a prevention framework. J Pediatr Psychol. 2018;43:237-242.
Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006;47:22-29.
Brown M, Farquhar-Smith P. Pain in cancer survivors; filling in the gaps. Br J Anaesth. 2017;119:723-736.
Tabone MD, Rodary C, Oberlin O, Gentet JC, Pacquement H, Kalifa C. Quality of life of patients treated during childhood for a bone tumor: assessment by the Child Health Questionnaire. Pediatr Blood Cancer. 2005;45:207-211.
Eiser C, Darlington AS, Stride CB, Grimer R. Quality of life implications as a consequence of surgery: limb salvage, primary and secondary amputation. Sarcoma. 2001;5:189-195.
Armstrong GT, Sklar CA, Hudson MM, Robison LL. Long-term health status among survivors of childhood cancer: does sex matter? J Clin Oncol. 2007;25:4477-4489.
Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28:3284-3291.
Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302:1985-1992.
Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005;23:8697-8705.
Simanski CJ, Althaus A, Hoederath S, et al. Incidence of chronic postsurgical pain (CPSP) after general surgery. Pain Med. 2014;15:1222-1229.
Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30:3687-3696.
Paulino AC, Nguyen TX, Mai WY. An analysis of primary site control and late effects according to local control modality in non-metastatic Ewing sarcoma. Pediatr Blood Cancer. 2007;48:423-429.
Röder C, Vogel R, Burri L, Dietrich D, Staub LP. Total hip arthroplasty: leg length inequality impairs functional outcomes and patient satisfaction. BMC Musculoskelet Disord. 2012;13:95.
Lietman SA, Joyce MJ. Bone sarcomas: overview of management, with a focus on surgical treatment considerations. Cleve Clin J Med. 2010;77(Suppl 1):S8-S12.
Tang MH, Pan DJ, Castle DJ, Choong PF. A systematic review of the recent quality of life studies in adult extremity sarcoma survivors. Sarcoma. 2012;2012:171342.

Auteurs

Melina Heinemann (M)

Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Department of Paediatric Haematology and Oncology, University Hospital Münster, Münster, Germany.
Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Christiane Hoffmann (C)

Orthopaedic Hospital Volmarstein, Wetter, Germany.
Department of Orthopaedics and Tumour Orthopaedics, University Hospital Münster, Münster, Germany.

Jendrik Hardes (J)

Department of Orthopaedics and Tumour Orthopaedics, University Hospital Münster, Münster, Germany.
Department of Oncologic Musculoskeletal Surgery, University Hospital Essen, Essen, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Wiebke Guder (W)

Department of Orthopaedics and Tumour Orthopaedics, University Hospital Münster, Münster, Germany.
Department of Oncologic Musculoskeletal Surgery, University Hospital Essen, Essen, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Arne Streitbürger (A)

Department of Orthopaedics and Tumour Orthopaedics, University Hospital Münster, Münster, Germany.
Department of Oncologic Musculoskeletal Surgery, University Hospital Essen, Essen, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Miriam Götte (M)

Department of Paediatric Haematology and Oncology, University Hospital Münster, Münster, Germany.
Paediatrics III, University Hospital Essen, Essen, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Theresa Luisa Welz (TL)

Paediatrics III, University Hospital Essen, Essen, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Heribert Jürgens (H)

Department of Paediatric Haematology and Oncology, University Hospital Münster, Münster, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Andreas Ranft (A)

Department of Paediatric Haematology and Oncology, University Hospital Münster, Münster, Germany.
Paediatrics III, University Hospital Essen, Essen, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Volker Vieth (V)

Department of Radiology, University Hospital Münster, Münster, Germany.
Department of Clinical Radiology, Klinikum Ibbenbüren, Ibbenburen, Germany.

Matthias Weckesser (M)

Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Michael Schäfers (M)

Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Lars Stegger (L)

Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.

Uta Dirksen (U)

Department of Paediatric Haematology and Oncology, University Hospital Münster, Münster, Germany.
Paediatrics III, University Hospital Essen, Essen, Germany.
West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany.
DKTK, German Cancer Research Centre, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH